News
Presentation by trial principal investigator at the 2025 SNO/ASCO CNS Metastases Conference Plus will also host an educational symposium with leading experts titled, “Reimagining Your Approach to ...
In 1997, Victoria teen Reena Virk was lured to a party where she was swarmed and violently assaulted. Sim, then 15 years old, ...
Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the portfolio company Umecrine Cognition has raised ...
The Pentagon has acknowledged that an Iranian ballistic missile hit Al Udeid Air Base in Qatar in June during an Iranian ...
Amarna Therapeutics and NorthX Biologics finalized an agreement to advance Nimvec AM510 gene therapy toward clinical trials for Type 1 Diabetes. Now in its fourth year, the MM+M Media Summit brings ...
With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help ...
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® ...
More than 17 million people in conflict-torn Yemen are going hungry, including over one million children under the age of ...
Francisco Rodriguez Jr has returned an “adverse analytical finding” in his Voluntary Anti-Doping Association (VADA) drug test ...
The ReSPECT-LM dose optimization trial benefits from a $17.6 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT), the second largest public funding source for cancer ...
GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results